We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

1 hedge funds and large institutions have $425K invested in Revance Therapeutics, Inc. in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 170 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 173 → 1 (-172)

100% less capital invested

Capital invested by funds: $249M → $425K (-$249M)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 170

Holders
1
Holders Change
-172
Holders Change %
-99.42%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
170
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$26.1M
2
BCM
Beryl Capital Management
California
-$18M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$17.1M
4
OBAM
ODDO BHF Asset Management
France
-$15.5M
5
Fidelity International
Fidelity International
Bermuda
-$12.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
DekaBank Deutsche Girozentrale
1
DekaBank Deutsche Girozentrale
Germany
$425K – – –
IA
2
IFP Advisors
Florida
$44 – – –
BlackRock
3
BlackRock
New York
– -$26.1M -8,597,418 Closed
BCM
4
Beryl Capital Management
California
– -$18M -5,935,009 Closed
Vanguard Group
5
Vanguard Group
Pennsylvania
– -$17.1M -5,625,091 Closed
OBAM
6
ODDO BHF Asset Management
France
– -$15.5M -5,100,000 Closed
Fidelity International
7
Fidelity International
Bermuda
– -$12.8M -4,196,095 Closed
AllianceBernstein
8
AllianceBernstein
Tennessee
– -$10.6M -3,497,112 Closed
Squarepoint
9
Squarepoint
New York
– -$9.62M -3,164,943 Closed
MF
10
Magnetar Financial
Illinois
– -$7.77M -2,556,345 Closed
State Street
11
State Street
Massachusetts
– -$7.41M -2,439,140 Closed
AAM
12
Alpine Associates Management
Florida
– -$7.14M -2,349,966 Closed
Geode Capital Management
13
Geode Capital Management
Massachusetts
– -$6.99M -2,297,582 Closed
GCL
14
Glazer Capital LLC
New York
– -$5.93M -1,950,000 Closed
NM
15
Newtyn Management
New York
– -$5.5M -1,810,000 Closed
Adage Capital Partners
16
Adage Capital Partners
Massachusetts
– -$5.03M -1,653,689 Closed
Millennium Management
17
Millennium Management
New York
– -$4.72M -1,551,372 Closed
UBS Group
18
UBS Group
Switzerland
– -$4.51M -1,483,040 Closed
AA
19
AQR Arbitrage
Connecticut
– -$4.3M -1,413,103 Closed
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
– -$4.16M -1,367,343 Closed
Qube Research & Technologies (QRT)
21
Qube Research & Technologies (QRT)
United Kingdom
– -$4.04M -1,328,525 Closed
JP Morgan Chase
22
JP Morgan Chase
New York
– -$3.95M -1,298,822 Closed
GF
23
Gabelli Funds
New York
– -$3.84M -1,262,487 Closed
Franklin Resources
24
Franklin Resources
California
– -$3.53M -1,161,382 Closed
CC
25
CIBRA Capital
United Kingdom
– -$3.47M -1,139,979 Closed
1
2 3 4 5

RVNC Hedge Fund Activity: Q1 2025 in Review

1 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2025, worth a combined $425K — down 100% from $249M a quarter earlier.

Sellers outnumbered buyers: 170 funds closed out of RVNC and 0 opened new positions — a net loss of 170 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $26.1M sold.

  • 1 institutional investor held Revance Therapeutics, Inc. (RVNC) as of Q1 2025, down from 173 in Q4 2024.
  • Funds reported $425K of Revance Therapeutics, Inc. stock for Q1 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Revance Therapeutics, Inc. positions in Q1 2025 and 170 closed out, a net change of -170 holders.
  • The largest Revance Therapeutics, Inc. seller in Q1 2025 was BlackRock, an estimated $26.1M sold.

Based on aggregated 13F filings for Q1 2025.